ライフサイエンスコーパス: unacceptably

1 stic model to show that this metric is often unacceptably biased.

2 e pro-drug depends on (a) elimination of the unacceptably bitter taste of free erythromycin, (b) its

3 e against women by intimate partners remains unacceptably common worldwide.

4 and recurrences of cutaneous lesions remain unacceptably frequent among survivors of neonatal herpes

5 he many forms of child maltreatment exact an unacceptably heavy toll on our children.

6 nistic fungal infections continue to take an unacceptably heavy toll on the most disadvantaged living

7 , the incidence of anastomotic leaks remains unacceptably high ( approximately 10%) even when perform

8 valence of stunting and underweight remained unacceptably high (30.0%, 95% CI 27.0-33.0, for stunting

9 situation where the rate of misdiagnosis is unacceptably high (up to 43%).

10 miting neutropenia and thrombocytopenia were unacceptably high after the doses of either TPT or PTX-2

11 While maternal mortality remains unacceptably high among all racial and ethnic groups in

12 man papillomavirus-associated anal cancer is unacceptably high among HIV-positive men who have sex wi

13 h as intimate partner violence (IPV), remain unacceptably high among women in South Africa.

14 d mortality for high-risk older patients was unacceptably high and abrogated the reduction in relapse

15 Malaria cases and deaths remain unacceptably high and are resurgent in several settings,

16 Mortality in sepsis remains unacceptably high and attempts to modulate the inflammat

17 fungal treatments, mortality rates are still unacceptably high and drug resistance is increasing.

18 th penicillin and ampicillin disk tests were unacceptably high and precluded recommended testing of t

19 evere diarrhea and/or cutaneous toxicity was unacceptably high at OSI-774 doses exceeding 150 mg/d.

20 rate of severe myelosuppressive effects was unacceptably high at TMZ doses exceeding 150 mg/m(2)/d i

21 rstitial and malignant lung diseases remains unacceptably high because control measures are not imple

22 ue to sex-specific conditions, to reduce the unacceptably high burden of ASCVD in women.

23 Rapid reduction of the unacceptably high burden of TB in high HIV prevalence se

24 a venous thrombosis rate that was considered unacceptably high by the study oversight committee (thro

25 pending food emergencies that otherwise have unacceptably high case fatality rates.

26 This results in unacceptably high costs for exhaustive genotyping and pr

27 Mortality from cardiogenic shock remains unacceptably high despite early coronary revascularizati

28 not acceptable (50%) and their recipient had unacceptably high donor-specific antibodies (28%).

29 ors were unacceptable, and 22 recipients had unacceptably high donor-specific antibodies.

30 market exclusivity has been associated with unacceptably high drug costs, both for newly developed d

31 wildlife, and (4) surface impoundments pose unacceptably high ecological risks regardless of locatio

32 ty for periodic chemical cleaning, and incur unacceptably high energy cost while also leaving an envi

33 irus disease, the case fatality rate remains unacceptably high even when patients are treated with th

34 the inbreeding loads considered, CM leads to unacceptably high extinction risks and, as a result, to

35 equired for metagenome sequencing has led to unacceptably high false discovery rates (FDR).

36 ost currently applied methods suffer from an unacceptably high false positive rate.

37 ch-counting and model-based methods may have unacceptably high false-discovery rates leading to overe

38 However, unacceptably high false-negative rates have been reporte

39 tivity, SN examination resulted in either an unacceptably high false-positive rate (20%) or a low sen

40 (NCNs) in 24-50% of subjects, suggesting an unacceptably high false-positive rate.

41 Lower thresholds resulted in unacceptably high false-positive rates (ie, cysts that a

42 ositive, error rates between BMD and DD were unacceptably high for ampicillin-sulbactam (VM error, 9.

43 eover, plasmapheresis was associated with an unacceptably high frequency of infectious complications.

44 Blood pressure levels remain unacceptably high in about half of such patients.

45 Incidence densities in MSM are unacceptably high in countries as diverse as China, Keny

46 often associated with thrombocytopenia, was unacceptably high in HP and MP patients treated at 572 m

47 Maternal and perinatal mortality are still unacceptably high in many countries despite steep increa

48 Stunting rates remain unacceptably high in many regions, including sub-Saharan

49 Rates of new HIV acquisition remain unacceptably high in most populations in low-income, mid

50 Mortality remains unacceptably high in patients with heart failure and red

51 Childhood growth faltering remains unacceptably high in sub-Saharan Africa.

52 Mortality from severe malaria remains unacceptably high in sub-Saharan Africa.

53 for pediatric heart transplantation remains unacceptably high in the current era.

54 t the recommended dose is associated with an unacceptably high incidence of AE; in such patients, the

55 fecting women of childbearing age, causes an unacceptably high incidence of irreversible premature ov

56 Removal of less than 3.5 glands has an unacceptably high incidence of persistent HPT (42%), whe

57 hat were withdrawn from the market due to an unacceptably high incidence of severe hepatotoxicity.

58 Due to unacceptably high interlaboratory variation in caspofung

59 ceptibility of Candida to caspofungin due to unacceptably high interlaboratory variation of caspofung

60 Tuberculosis incidence is unacceptably high irrespective of HIV status in black Af

61 mponents, the generated heat loads result in unacceptably high junction temperatures and reduced comp

62 rk, in which a benchmark value represents an unacceptably high level of a contaminant or contaminant

63 um) cultivars and can result in commercially unacceptably high levels of alpha-amylase in harvest-rip

64 d (minor error rate, 63.6%) methods produced unacceptably high levels of errors when testing penicill

65 nately, however, these optodes suffered from unacceptably high levels of sodium interference under ph

66 lay of 24 h prior to adding to UPT led to an unacceptably high loss of assay sensitivity.

67 are providers and healthcare institutions at unacceptably high malpractice risk?

68 wide, especially as the US continues to face unacceptably high maternal mortality rates.

69 ningitis remains a devastating disease, with unacceptably high morbidity and mortality despite advanc

70 syndrome (ARDS) and trauma continue to have unacceptably high morbidity and mortality, with progress

71 of the CARRS score identifies patients with unacceptably high mortality after HTx and those with a s

72 Renal ischemic reperfusion injury results in unacceptably high mortality and morbidity during the per

73 associated with this syndrome, including its unacceptably high mortality and the lack of effective ph

74 rbidity worldwide and are associated with an unacceptably high mortality despite the availability of

75 econceptualisation of policies to reduce the unacceptably high mortality in twins in Eastern and Sout

76 This Review, in addressing the unacceptably high mortality of patients with liver disea

77 th a donor pool too small to meet demand and unacceptably high mortality on transplant waiting lists,

78 respiratory distress syndrome (ARDS) has an unacceptably high mortality rate (35%) and is without ef

79 ently below 15 mL/min per 1.73 m(2)--have an unacceptably high mortality rate.

80 ition, which continues to be associated with unacceptably high mortality.

81 nt pathways and interventions to address the unacceptably high mortality.

82 HIV-infected patients with MDR-TB have unacceptably high mortality; both antiretroviral and ant

83 ificantly more false-positive results and an unacceptably high number of indeterminate results.

84 nual retinal exams for diabetes patients, an unacceptably high number of patients are not screened fo

85 terminate the trial if the toxicity rate is unacceptably high or the complete remission (CR) rate is

86 In an unacceptably high percentage of these patients, variabil

87 We document an unacceptably high prevalence of uncontrolled BP and HbA1

88 K due to uncertainty of clinical benefits or unacceptably high prices.

89 otease inhibitors as monotherapy has been an unacceptably high rate of emergence of resistance.

90 ove baseline, but also was accompanied by an unacceptably high rate of endometrial hyperplasia.

91 d to exhaustion and thereby contribute to an unacceptably high rate of intermediate and long-term gra

92 vudine regimen resulted in an unexpected and unacceptably high rate of nonresponse and incidence of K

93 t seven patients were enrolled because of an unacceptably high rate of rejection (7/7 = 100%).

94 cal health issues in the United States, with unacceptably high rates and racial, ethnic, and geograph

95 tion of mcr-1-resistant isolates, there were unacceptably high rates of errors for both susceptible a

96 se lower safety margins were associated with unacceptably high rates of failed defibrillation and sud

97 response to infection and is associated with unacceptably high rates of mortality and morbidity.

98 r, patients with high-risk tumors still have unacceptably high rates of recurrence and disease progre

99 to current cytotoxic chemotherapy and suffer unacceptably high rates of relapse, supporting the need

100 HP patients, with higher doses resulting in unacceptably high rates of severe hematologic toxicity.

101 ed racial and ethnic groups leave science at unacceptably high rates.

102 ern and southern Africa continue to occur at unacceptably high rates.

103 by local excision alone are associated with unacceptably high recurrence rates.

104 ependent data monitoring committee due to an unacceptably high relapse rate in the PET-negative patie

105 Due to the unacceptably high risk for mortality from open heart sur

106 t extracts is not recommended because of the unacceptably high risk of anaphylaxis.

107 use of anticoagulants may be associated with unacceptably high risk of bleeding complications.

108 diverse compounds bind to hERG and carry an unacceptably high risk of causing arrhythmias.

109 m fungal cultures are uncommon, but carry an unacceptably high risk of postoperative fungal infection

110 but 80 mg simvastatin is associated with an unacceptably high risk of statin-induced myopathy.

111 uld be given in limiting its use to cases of unacceptably high risk of stroke during aortic cross-cla

112 procedures are particularly associated with unacceptably high short and long-term morbidity and mort

113 ion that younger and smaller infants face an unacceptably high surgical risk.

114 Unacceptably high syphilis prevalence among MSM warrants

115 or China to intensify efforts for those with unacceptably high under-5 mortality rates.

116 L PICC design used in this study resulted in unacceptably high venous thrombosis rates.

117 ere species-specific differences that led to unacceptably high VME for Candida dubliniensis with all

118 mirabilis) and P. aeruginosa demonstrated an unacceptably high VME rate of 7.1% despite 95.2% EA, 99.

119 However, all agents had unacceptably high VME rates using genotypic testing beca

120 This has created unacceptably high waiting-list mortality for lung transp

121 h oral squamous cell carcinoma (OSCC) remain unacceptably high with disfiguring treatment options and

122 Although mortality in all groups remains unacceptably high, additional emphasis should be placed

123 tality and morbidity after lung resection is unacceptably high, and has changed little in the last 20

124 sepsis-induced acute kidney injury (AKI) is unacceptably high, especially in the elderly.

125 ient diagnosis of HIV-associated TB remained unacceptably high, even in South Africa.

126 the probability of sign inconsistency can be unacceptably high, even when the conditions for QTL dete

127 ver disease in district general hospitals is unacceptably high, indicating the need to develop a mast

128 y rate for acute kidney injury (AKI) remains unacceptably high, likely owing to extrarenal organ dysf

129 come and middle-income countries (LMICs) are unacceptably high, requiring both collaborative global e

130 sub-Saharan Africans, maternal mortality is unacceptably high, with >400 deaths per 100,000 births c

131 The global incidence of tuberculosis remains unacceptably high, with new preventative strategies need

132 ients with acute renal failure (ARF) remains unacceptably high.

133 e residual disability and death rate remains unacceptably high.

134 eas--including immunosuppressant use--appear unacceptably high.

135 ence in the population at large has remained unacceptably high.

136 ne report delayed nausea, the proportion was unacceptably high.

137 th chloroquine+sulfadoxine-pyrimethamine was unacceptably high.

138 Mortality rates in ESRD are unacceptably high.

139 Morbidity after pancreatectomy remains unacceptably high.

140 hat the morbidity and mortality rates remain unacceptably high.

141 ever, the rate of distant metastasis remains unacceptably high.

142 TB) in hospital inpatients in Africa remains unacceptably high.

143 the recurrence rate in this disease remains unacceptably high.

144 r transplant (LT) waitlist mortality remains unacceptably high.

145 ethnic and educational health inequities is unacceptably high.

146 ults dying at home has decreased but remains unacceptably high.

147 ates of heart failure hospitalization remain unacceptably high.

148 n high-prevalence settings in Africa remains unacceptably high.

149 e incidence of acute rheumatic fever remains unacceptably high.

150 and the rate of progression to ESRD remained unacceptably high.

151 enting cells, making potential vaccine costs unacceptably high.

152 countries where the stunting burden remains unacceptably high.

153 economic burden of heart failure (HF) remain unacceptably high.

154 prescribing in dementia in Scotland remains unacceptably high.

155 ents with acute liver failure (ALF) is still unacceptably high.

156 anticancer drugs entering clinical trials is unacceptably high.

157 ular failure; morbidity and mortality remain unacceptably high.

158 e of aligner, the rate of false positives is unacceptably high.

159 treatment of acute leukemia, relapse remains unacceptably high.

160 th mean and SD in these circumstances may be unacceptably high.

161 llbirths remains unchanged since 2011 and is unacceptably high: an estimated 2.6 million in 2015.

162 g 29% more true positives than LBC alone, it unacceptably increased excess colposcopy referral by 94%

163 therapeutic efficacy of a new therapy is not unacceptably inferior to that of standard therapy are ca

164 for some individuals sulfur gases can cause unacceptably large (up to 500%) errors, making the sulfu

165 distribution of origins would generate some unacceptably large interorigin distances.

166 ncorporation of Bonferroni correction led to unacceptably large limits of detection, severely decreas

167 ly structural lead (1f, SC-236) exhibited an unacceptably long plasma half-life, a number of pyrazole

168 equipment and infrastructure requirements to unacceptably long turnaround times.

169 aculty diversity at academic institutions is unacceptably low (<6%) and has remained unchanged in the

170 high or the complete remission (CR) rate is unacceptably low compared with the rates of these events

171 dentify factors that may contribute to these unacceptably low detection rates.

172 ed as a technically demanding procedure with unacceptably low efficiency using either contemporary tr

173 vDS5), from a smaller, high-risk group with unacceptably low EFS at 47.6% (qPET > 3; refers to vDS5)

174 assays in individuals presenting for PEP is unacceptably low for bDNA-based testing and possibly acc

175 nkton; however, the signal-to-noise ratio is unacceptably low in extremely oligotrophic regions, whic

176 However, its coverage remains unacceptably low in many countries.

177 are not water soluble and consequently have unacceptably low oral bioavailabilities.

178 ely difficult to treat successfully, and the unacceptably low overall survival rates mandate that we

179 while yielding a rapid in-office result, had unacceptably low sensitivity.

180 III criteria for chronic constipation but an unacceptably low specificity (51.3%, 95%CI: 48.8, 53.8)

181 l applications of gene delivery, albeit with unacceptably low transfection efficiencies (TE).

182 sensitivities of the toxin immunoassays were unacceptably low, while the LightCycler real-time PCR as

183 despite this progress, survival has remained unacceptably low.

184 patients with a suspected IEI, which remains unacceptably low.

185 treatment for children with malaria remains unacceptably low.

186 l publication or reporting of results remain unacceptably low.

187 lly or morphologically defined cell types is unacceptably low.

188 Us based on risk-adjusted mortality rate was unacceptably low.

189 quently, worldwide access to radiotherapy is unacceptably low.

190 0% was desired, and 80% was considered to be unacceptably low.

191 effective, and current utilization rates are unacceptably low.

192 rates for patients with advanced CRC remain unacceptably low.

193 igher threshold values (>20%) resulted in an unacceptably lower sensitivity for tumors.

194 across the country and survival rates remain unacceptably poor for many cancers.

195 Resolution was unacceptably poor if the samples dissolved in methanol w

196 initions for detecting RNFL thinning have an unacceptably poor level of specificity, and that more st

197 r psychiatric disorders(6), and outcomes are unacceptably poor(7).

198 However, overall survival rates remain unacceptably poor, with only 65% of patients surviving l

199 with each diagnosis whose prognosis remains unacceptably poor.

200 eated non-small-cell lung cancer (NSCLC) are unacceptably poor.

201 Survival of elderly burn patients remains unacceptably poor.

202 s associated with smoking, the habit remains unacceptably prevalent.

203 fection as reflected by its potential for an unacceptably renewed viral onslaught.

204 The useful lifetime was unacceptably short for the sensor that employed the bare

205 ibiotic susceptibility testing (AST) remains unacceptably slow (1-2 d), and innovative approaches for

206 evaluate a single query at a time and can be unacceptably slow when the number of sequences in the qu

207 his approach is life sustaining, it is still unacceptably suboptimal with poor clinical outcomes of p

208 Unacceptably, this situation that has remained unchanged

209 the disease or that the treatment will prove unacceptably toxic.

210 weeks thereafter until disease progression, unacceptably toxicity, or the end of study.